Several new HIV/HCV coinfection resources for the HIV workforce were recently released by partners of the U.S. Department of Health and Human Services. Here's the department's quick roundup.
The link between frailty and chronic disease development; Atripla’s long-term efficacy; the dangers of restrictive eligibility criteria for hepatitis C treatment; nicotine metabolism rates in people living with HIV.
HIV-associated neurocognitive disorders, including dementia, may be well-documented issues, but they're still being understood. New research answers some questions providers may have about HIV's impact on the brain.
E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.
Our series on mentor-mentee researchers continues with Ellen Eaton, M.D., and Kelsie Dodson, with the University of Alabama at Birmingham.
Cholesterol guidelines may underestimate statin value; shifting from Ryan White CARE Act to Affordable Care Act coverage; HCV seroconversion and CD4 count suppression; HCV reinfection odds by risk group.
The number of people who inject drugs has soared, yet many drug patients are not checked for the virus that can damage the liver.
In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.
Integrase inhibitors have revolutionized HIV treatment, as a glance at HIV treatment guidelines over the past few years makes clear. And with good reason: They're well tolerated, have a high barrier to resistance, and are potent as all get out. But t...
Debates about the role of abacavir (Ziagen, ABC) in the development of cardiovascular disease in persons living with HIV have raged for over a decade, and a kind of stalemate has been achieved between those who are and are not convinced of a link. Wh...